D. Malón

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2021, Pharmacogenomics and personalized medicine.

Metabolic synthetic lethality: a randomized, phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

Gion, S. Morales, J. Cortés, 2019 .

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Miguel Ángel Martínez, S. Morales, M. C. Moreno-Ortiz, 2020, Breast Cancer Research.

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2020, World journal of gastroenterology.

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

R. Colomer, J. Hornedo, S. Mourón, 2019, Breast Cancer Research.

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2022, Pharmaceutics.

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

R. Colomer, J. Hornedo, S. Mourón, 2019, Breast Cancer Research.

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2023, Cancers.

Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients

C. Jara, B. Losada, D. Malón, 2018, Clinical and Translational Oncology.

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

F. Mulero, S. Morales, J. Cortés, 2019, Clinical Cancer Research.

Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2021, International journal of molecular sciences.

Adjuvant chemotherapy for stages II, III and IV of colon cancer

A. Carrato, C. Grávalos, P. García-Alfonso, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Biliary cystadenocarcinoma with mesenchymal stroma

H. Cortés-Funes, C. Gómez-Martín, D. Malón, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

S. Servitja, R. Andrés, A. Llombart-Cussac, 2020, Breast.